Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Go Back

Share this story

Comments


Related articles


Prof Alesch Vantage Vercise

sponsored article

Advances

How state-of-the-art tech allows DBS upgrades without extra head surgery

VIDEO: Prof Alesch explains how special adapters can upgrade DBS patients

READ MORE
Kim Petrie with The Trews

Interviews

Kim Petrie: “How I raised $250,000 for Parkinson’s research”

Kim Petrie tells us how she raised $250,000 to fight Parkinson’s

READ MORE
Speech pathologist John Dean

Resources & Tools

6 tools to improve speech in people with Parkinson’s

Tools and tips to improve Parkinson’s speech

READ MORE